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Abstract. Spoelstra-de Man AME, Smulders YM,
Dekker JM, Heine RJ, Bouter LM, Nijpels G,
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Amsterdam; and University Hospital Maastricht,
Maastricht; the Netherlands). Homocysteine levels
are not associated with cardiovascular autonomic
function in elderly Caucasian subjects without or
with type 2 diabetes mellitus: the Hoorn Study.
J Intern Med 2005; 258: 536–543
Objective. Homocysteine and cardiovascular
autonomic function are both predictors of
cardiovascular disease and death, particularly in
patients with diabetes. The mechanism by which
homocysteine causes disease is unknown. The
objective of our study was to determine whether
hyperhomocysteinaemia is associated with impaired
cardiovascular autonomic function in an age-, sex-,
and glucose tolerance-stratified sample of an elderly
Caucasian population.
Methods. We studied 609 subjects, 252 with
normal glucose metabolism, 173 with impaired
glucose metabolism, and 184 with type 2 diabetes.
Cardiac cycle duration (RR interval) and continuous
finger arterial pressure were measured under three
conditions: during (i) spontaneous breathing, (ii) six
deep breaths over 1 min, and (iii) an active change
in position from lying to standing. From these
readings, 10 parameters of autonomic function
were assessed (three Ewing tests, six heart rate
variability tests and one test of baroreflex
sensitivity). These 10 measurements were
summarized in a single cardiovascular autonomic
dysfunction score (CADS).
Results. Comparing values of autonomic function
measures in the lowest versus the highest quartile of
homocysteine revealed no significant association
between homocysteine level and autonomic
function in the whole study group, nor in the
individual glucose tolerance groups. Multiple
adjustment for age, sex, waist-to-hip ratio, serum
creatinine, use of antihypertensives and fasting
insulin, confirmed this result. We found no
evidence of effect modification of glucose tolerance
status on the association between homocysteine and
autonomic dysfunction (P for interaction for
CADS ¼ 0.79).
Conclusions. There is no evidence for an
association between homocysteine levels and
cardiovascular autonomic function in either
diabetic or nondiabetic subjects. Cardiovascular
autonomic dysfunction does not help explain why
hyperhomocysteinaemia is related to cardio-
vascular mortality.
Keywords: autonomic nervous system diseases,
diabetes mellitus type 2, glucose metabolism
disorders, homocysteine, hyperhomocysteinaemia.
Introduction
Hyperhomocysteinaemia is a risk factor for mortality
in the general population [1]. Homocysteine is a
stronger risk factor for mortality in type 2 diabetic
patients than in nondiabetic subjects [2]. The
mechanism underlying the greater susceptibility of
diabetic individuals to the adverse effects of
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hyperhomocysteinaemia has not been elucidated.
Autonomic dysfunction might play a role, as
cardiovascular autonomic dysfunction, even if sub-
clinical, is associated with sharply increased cardio-
vascular mortality [3], particularly in diabetic
patients, but also in the nondiabetic population [4,
5]. Hyperhomocysteinaemia might contribute to the
pathogenesis of autonomic dysfunction. Neurotox-
icity of increased homocysteine levels may be caused
by direct toxic effects, or by dysfunction of the vasa
nervorum [6–8].
Previously, only two studies, both in diabetic
subjects, have specifically addressed the association
between hyperhomocysteinaemia and autonomic
dysfunction. However, one study was small, invol-
ving only 65 subjects [6], and in the other study the
diagnosis of autonomic neuropathy was based on
only a single test [9]. Moreover, as both studies only
included diabetic patients, possible effect modifica-
tion of glucose tolerance with regard to the associ-
ation between homocysteine and autonomic
dysfunction could not be addressed.
In view of the unclear pathogenesis of hyperhom-
ocysteinaemia-related cardiovascular mortality, the
possible association between homocysteine and
cardiovascular autonomic function is important.
In this population-based study, we investigated
whether an association exists between hyperhomo-
cysteinaemia and cardiovascular autonomic func-
tion in subjects without and with type 2 diabetes.
Materials and methods
All participating individuals were involved in the
Hoorn Study, the baseline measurements of which
were conducted from 1989 to 1992. For this study,
a random sample of all Caucasian individuals aged
50–75 years was drawn from the municipal popu-
lation registry office of Hoorn (the Netherlands);
2484 subjects participated (response rate 71%). An
extensive cardiovascular investigation was per-
formed in an age-, sex-, and glucose tolerance-
stratified random subsample [n ¼ 708, of whom
631 responded (89%)] as described in detail else-
where [10]. The Hoorn Study was carried out in
accordance with the Declaration of Helsinki (2000)
and was approved by the Ethical Review Committee
of the University Hospital ‘Vrije Universiteit’ Amster-
dam. Informed consent was obtained from all
participants.
Measurements
Height and weight were measured barefoot wearing
light clothes only. Double readings of systolic and
diastolic (Korotkoff V) blood pressure were obtained
on two separate occasions on the right arm with the
subject in a sitting position. ‘Actual’ hypertension
was defined as a mean systolic blood pressure of
‡160 mmHg and/or a mean diastolic pressure of
‡95 mmHg, with or without anti-hypertensive
medication. Impaired glucose metabolism and type
2 diabetes mellitus were diagnosed according to the
1999 World Health Organisation criteria applied to
the mean of two standard oral glucose tolerance
tests [11]. We determined levels of fasting serum
total cholesterol, HDL cholesterol and triglycerides
by enzymatic techniques (Boehringer-Mannheim,
Mannheim, Germany). The Friedewald formula
was used to calculate the LDL cholesterol concen-
tration, except in subjects with serum triglyceride
levels >8.0 mmol l)1 (N ¼ 3). HbA1c was deter-
mined by means of ion exchange high-performance
liquid chromatography (HPLC). The waist-to-hip
ratio was measured as previously described [10].
Body mass index was calculated as weight divided
by height squared (kg m)2). All laboratory meas-
urements were carried out by technicians unaware
of the subjects’ history of cardiovascular disease and
glucose tolerance status.
Measurement of serum total homocysteine
Fasting blood samples were centrifuged within 1 h
after drawing blood. Serum was stored at )20 C for
6 years. There is good evidence that, under these
conditions, serum total homocysteine levels are
stable for many years [12]. Serum total (free plus
protein bound) homocysteine level was measured by
using tri-n-butylphosphine as the reducing agent
and ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-
sulphonate as the thiol-specific fluorochromophore,
followed by HPLC with fluorescence detection [13].
The intra- and interassay coefficients are 2.1% and
5.1% respectively.
Autonomic function tests
For the assessment of cardiovascular autonomic
function, study participants were asked to refrain
from smoking and drinking coffee for 2 h prior to
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the examination. The tests took place between
8.30 a.m. and 4 p.m., at least 1 h after a light
meal. A quiet ambience was ensured, with a room
temperature between 19 and 22 C. All tests were
performed by a single investigator, who was
unaware of the individual’s glucose tolerance status.
The duration of one cardiac cycle (RR interval)
and continuous finger arterial pressure were meas-
ured under three conditions: (i) during spontaneous
breathing for 3 min in supine position, (ii) during
1 min with six deep breaths in supine position, and
(iii) during an active position change from lying to
standing. The correct breathing frequency at six
breaths per minute was controlled by the investi-
gator. The record was discarded if off-line spectral
analysis showed that breathing was not performed
at the appropriate frequency. After a resting period
of at least 10 min, testing was started, whilst each
separate test started with a resting period of at least
1 min. During the tests, RR intervals and blood
pressure were continuously recorded on a PC-based
data-acquisition system. We obtained RR intervals
from an electrocardiogram by a hardware QRS
detector with an accuracy of one millisecond (ms).
Blood pressure was recorded using the FinapresTM
method (Finger Arterial Blood Pressure, Ohmeda
BP2000, Englewood, CO, USA) [14]. Systolic blood
pressure values were obtained from the sampled
continuous blood pressure signal by means of an
automatic procedure, which was verified by visual
inspection.
We computed 10 measures of cardiovascular
autonomic function from the RR interval and the
SBP recordings under the three respective condi-
tions, with computerized data analysis using a
system developed locally by the Department of
Medical Physics, Vrije Universiteit, Amsterdam, the
Netherlands, as previously described in detail [15].
Table 1 gives the definition and the computational
information of the 10 measures [3, 16–21].
Individual data were missing for the following
reasons: an incomplete test schedule, insufficient
Table 1 Overview of the 10 measures of cardiovascular autonomic function
Measure Unit Definition
During spontaneous breathing over 3 min in supine position
Mean NN ms The mean of all normal to normal, i.e. sinus rhythm, RR intervals
SDNN ms The standard deviation of all normal to normal, i.e. sinus rhythm, RR intervals
LF power ms2 Low frequency power, in absolute units: energy in the power spectrum between 0.004 and 0.12 Hz
HF power ms2 High frequency power, in absolute units: energy in the power spectrum between 0.12 and 0.40 Hz
LF/(LF + HF) The ratio of low frequency power to the sum of the low and high frequency power
During six deep breaths over 1 min in supine position
EI difference ms The mean expiration–inspiration difference in RR intervals over the six consecutive breaths
BRS ms mmHg)1 A measure of baroreflex sensitivity, computed as gain, i.e. ratio of the energy in the cross-spectrum
of systolic blood pressure and RR intervals, and the energy in the power spectrum of the RR interval;
all between 0.05 and 0.15 Hz and with a squared coherence (c2) of 0.5 or higher
During an active change in position from lying to standing
RR max ms The difference between the mean RR interval during 1 min of rest prior to standing up and the
minimum RR interval within 15 s after standing up
RR max/min Maximum RR interval between 15 and 30 s after standing up divided by minimum RR interval
within 15 s after standing up
SBP difference mmHg Systolic blood pressure after standing up (mean of 1.5–2 min after standing) minus systolic blood
pressure in supine position
Mean NN, mean of all sinus rhythm (normal-to-normal) RR intervals;
SDNN, standard deviation of all sinus rhythm (normal-to-normal) RR intervals;
LF power, low frequency power in the RR-interval spectrum between 0.04–0.12 Hz;
HF power, high frequency power in the RR-interval spectrum between 0.12–0.40 Hz;
LF/(LF + HF), ratio of low frequency power to the sum of low and high frequency power in the RR-interval spectrum;
EI difference, expiration-inspiration difference in RR intervals during breathing at 6/min;
BRS, baroreflex sensitivity;
RR max, maximal change in RR interval after standing up;
RR max/min, maximal RR interval between 15s and 30s after standing up divided by the minimal RR interval within 15s after stading up;
SBP difference, systolic blood pressure 1.5–2 min after standing up minus systolic blood pressure in supine position.
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quality data for processing (a poor blood pressure
signal or dysrhythmias), more than 10% non-sinus
beats in the total number of recorded beats or if
standing up took more than 10 s.
Statistical analysis
Routine parametric and nonparametric bivariate
tests were used, as appropriate, to test for group
differences. Based on the 10 measures of cardiovas-
cular autonomic function, a summary ‘cardiovas-
cular autonomic dysfunction score’ (CADS) was
constructed as follows: the results of each measure-
ment were divided into quartiles. A subject was
assigned 0 point if the result was in the most normal
quartile, 1 point if in the second quartile, 2 points if
in the third quartile, and 3 points if the test outcome
was in the most abnormal quartile. If all 10
measures were completed successfully, the scores
of each were added together. If one or two results
were missing (52 of 609 subjects), it was replaced by
the median score for this measurement. When three
or more results were missing the patient was
excluded for calculation of CADS (79 subjects). The
result is a CADS ranging from 0 (good) to 30 (poor).
We used t-tests to compare values of the autonomic
function measures in the lowest versus the highest
quartile of homocysteine, both in the whole group as
well as in the three separate glucose tolerance
groups. Multiple linear regression analysis was used
to identify independent determinants of CADS.
Because the study population was stratified by age,
gender and glucose tolerance, these three variables
were entered into the regression model, even when
they did not significantly contribute after other
variables were entered. In addition, we adjusted for
the determinants of autonomic function we have
previously described [15]. A two-sided P-value of
<0.05 was considered statistically significant. All
analyses were performed with SPSS 11.0 for
Windows 98 (SPSS Inc., Chicago, IL, USA).
Results
In 22 subjects, no autonomic function tests were
available, so final analyses were based on 609 of the
631 subjects. The group of individuals excluded
(n ¼ 22) was significantly older (mean 69 years vs.
64 years; P ¼ 0.001 by Student’s t-test) than those
included. In addition, they more often had diabetes
(45% vs. 26%, P < 0.001) and less often normal
glucose metabolism (32% vs. 46%, P < 0.05 both by
chi-square analysis).
Table 2 shows demographic and clinical data of
the study population in three categories of glucose
tolerance. Only a small number (29) of patients had
impaired fasting glycaemia. Therefore, we analysed
patients with impaired fasting glycaemia together
with the patients with impaired glucose tolerance, as
the impaired glucose metabolism group. Amongst
the noticeable findings in Table 2 is the absence of
an association between glucose tolerance categories
on the one hand, and renal function and homocy-
steine concentrations on the other. As described
previously, autonomic function parameters in this
population were most strongly associated with
glucose tolerance status and moderately associated
with age, sex, waist-to-hip ratio, use of antihyper-
tensives and fasting insulin [15] (data not shown).
Comparing values of autonomic function meas-
ures in the lowest versus the highest quartile of
homocysteine revealed no significant association
between homocysteine level and autonomic func-
tion in the whole study group (Table 3). Likewise,
analyses of homocysteine levels below and above
commonly used cut-off levels of both 12 and
15 lmol l)1 revealed no positive association be-
tween hyperhomocysteinaemia and autonomic
function, nor was there any indication in the data
of a threshold value of homocysteine above which a
positive association with autonomic function
became apparent. The three separate glucose tole-
rance groups did not differ with regard to the
absence of any correlation between the autonomic
function tests and homocysteine levels (data not
shown). In 79 subjects, the combined autonomic
function score CADS could not be calculated because
of three or more missing measurements. Therefore,
analyses on CADS were based on 530 subjects. As
illustrated in Fig. 1, no crude correlation between
homocysteine quartiles and CADS was apparent.
Multiple linear regression analysis, both crude and
with adjustment for glucose tolerance category, age,
sex, waist-to-hip ratio, serum creatinine, use of
antihypertensives and fasting insulin, confirmed
that no significant relationship existed between
homocysteine levels and both the individual auto-
nomic function measures as well as the combined
score (Table 4). We found no evidence of effect
modification of glucose tolerance status on the
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Table 3 Median values of autonomic function tests in the whole group for each quartile of homocysteine and t-test comparing values of













BRS (ms mmHg)1) 534 7.8 7.4 7.8 7.6 0.32
EI difference (ms) 568 161 150 146 144 0.24
HF power (ms2) 564 165 183 156 150 0.17
LF power (ms2) 564 240 192 184 230 0.43
Mean NN (ms) 564 950 923 920 936 0.76
LF/(LF + HF) 564 0.57 0.54 0.53 0.60 0.45
RR max (ms) 570 230 227 231 216 0.34
RR max/min 570 1.22 1.22 1.22 1.18 0.31
SBP difference (mmHg) 570 )6.3 )6.1 )6.3 )5.2 0.78
SDNN (ms) 564 35 31 34 35 0.10
CADS 530 13 15 14.5 13 0.81
CADS, combination score of the 10 autonomic function measures; n, number of subjects on which the analysis was performed. For
explanation of autonomic function tests and their abbreviations, see Table 1.
Table 2 Demographic and clinical data
Variable
NGM (n ¼ 252) IGM (n ¼ 173) DM2 (n ¼ 184)
Men Women Men Women Men Women
N 122 130 89 84 81 103
Age (years) 62 (8) 64 (7) 63 (7) 65 (7) 64 (7) 67 (6)
Anthropometric factors
Body mass index (kg m)2) 25.4 (2.6) 26.3 (3.6) 27.1 (3.5) 27.8 (3.9) 27.7 (3.3) 29.6 (4.9)
Waist-to-hip ratio 0.94 (0.06) 0.84 (0.07) 0.98 (0.07) 0.88 (0.07) 0.99 (0.07) 0.91 (0.07)
Blood pressure
Systolic (mmHg) 130 (17) 135 (19) 141 (19) 144 (21) 143 (17) 145 (19)
Diastolic (mmHg) 81 (10) 80 (10) 84 (9) 84 (10) 85 (10) 82 (10)
Hypertension (%) 28 21 44 39 59 46
Metabolic factors
HbA1c (%) 5.3 (0.5) 5.3 (0.5) 5.5 (0.5) 5.6 (0.5) 6.8 (1.6) 7.2 (1.8)
Fasting insulin 76 (30) 77 (37) 102 (50) 96 (52) 114 (52) 126 (64)
Total cholesterol (mmol l)1) 6.5 (1.0) 6.8 (1.2) 6.5 (1.2) 6.9 (1.0) 6.2 (1.2) 6.9 (1.3)
HDL cholesterol (mmol l)1) 1.2 (0.3) 1.5 (0.3) 1.2 (0.4) 1.4 (0.4) 1.1 (0.3) 1.2 (0.3)
Triglycerides (mmol l)1) 1.4 (0.5–5.1) 1.2 (0.5–4.2) 1.6 (0.6–10.5) 1.6 (0.8–4.9) 1.9 (0.4–6.7) 2.1 (0.6–14.0)
Homocysteine (lmol l)1) 13.5 (7.2) 11.6 (4.2) 14.0 (6.0) 12.0 (3.8) 12.0 (4.1) 11.9 (7.5)
Creatinine (lmol l)1) 99 (13) 84 (13) 98 (14) 84 (10) 102 (21) 84 (27)
Autonomic function measures
BRS (ms mmHg)1) 8.6 (0.8–35.8) 8.1 (1.7–27.8) 7.3 (0.6–25.6) 8.1 (1.8–40.1) 6.8 (0.8–18.8) 6.6 (1.1–23.0)
EI difference (ms) 196 (29–577) 156 (46–443) 176 (34–556) 145 (31–463) 130 (30–564) 124 (30–539)
HF power (ms2) 217 (7–7393) 198 (7–4521) 150 (8–3103) 136 (7–1877) 144 (4–5657) 101 (10–7116)
LF power (ms2) 344 (13–8093) 205 (7–3666) 247 (15–3441) 195 (27–1572) 265 (7–2471) 133 (3–2478)
Mean NN (ms) 979 (164) 973 (131) 950 (151) 920 (137) 945 (153) 870 (137)
LF/(LF + HF) 0.58 (0.17) 0.52 (0.19) 0.59 (0.19) 0.52 (0.20) 0.59 (0.19) 0.51 (0.19)
RR max (ms) 251 (87–944) 237 (60–487) 244 (60–514) 211 (75–493) 236 (60–547) 182 (63–525)
RR max/min 1.2 (1.0–2.1) 1.2 (1.0–2.1) 1.2 (1.0–1.9) 1.2 (1.0–1.6) 1.2 (1.0–1.8) 1.2 (1.0–1.8)
SBP difference (mmHg) )4 (13) )5 (15) )4 (13) )8 (15) )6 (17) )9 (16)
SDNN (ms) 37 (11–118) 35 (9–86) 31 (12–90) 31 (12–74) 31 (8–129) 24 (7–124)
CADS 12 (5) 13 (5) 13 (6) 15 (5) 14 (6) 17 (5)
Data are presented as mean (SD) or median (range). NGM, normal glucose metabolism, IGM, impaired glucose metabolism; DM2, diabetes
mellitus type 2; CADS, combined score of the ten autonomic function scores. For explanation of autonomic function tests and their
abbreviations, see Table 1.
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association between homocysteine and autonomic
dysfunction (P for interaction for CADS ¼ 0.79).
Discussion
In this study, we observed no association between
plasma homocysteine levels and cardiovascular
autonomic function in either diabetic or non-
diabetic subjects of an age-, sex- and glucose
tolerance-stratified random sample of an elderly
Caucasian population. These results do not support
the concept of an intermediate role for cardiovascu-
lar autonomic dysfunction in a causal relationship
between hyperhomocysteinaemia and cardiovascu-
lar mortality, either in non-diabetic or in diabetic
individuals.
Most previous studies addressing this topic inves-
tigated peripheral sensorimotor neuropathy and
showed no association with hyperhomocysteinae-
mia [22–25]. Only in two previous studies were data
on autonomic neuropathy collected. Ambrosch et al.
[6] investigated 65 patients with type 2 diabetes,
and found a positive association between homocy-
steine levels and presence of neuropathy, but ana-
lysed patients with peripheral sensorimotor
neuropathy, peripheral autonomic and/or cardio-
vascular autonomic neuropathy as a single group.
Separate data on autonomic neuropathy were not
presented, thus making comparison with our data
difficult. In the Appropriate Blood pressure Control
in Diabetes (ABCD) trial, Cohen et al. [26] did
perform separate analyses of autonomic and senso-
rimotor neuropathy and found an independent
association between hyperhomocysteinaemia and
diabetic autonomic neuropathy, but not with dia-
betic sensorimotor peripheral neuropathy. Two dif-
ferences between this study and ours are
noteworthy. First, in the ABCD trial only a single
cardiovascular autonomic test was performed (the
heart rate response to deep breathing). In addition,
differences in serum creatinine, although small,
were not accounted for in the multivariate analyses,
and may have confounded the outcome, as minor
increases in serum creatinine may represent signi-
ficant loss of glomerular filtration rate, which is
associated with increases in homocysteine level [27]
and with autonomic dysfunction [28–30]. In sum,
most studies [22–25, and the present study] found
no association between homocysteine levels and
presence of neuropathy, but two [6, 9] did, and the
reasons for this discrepancy remain to be clarified.
The strengths of our study are that it was large
and population-based, included both diabetic and
non-diabetic patients, and employed a number of
validated cardiovascular autonomic function tests.
The size of our study group allowed for the use of
subgroup analyses and multivariable regression
modelling. Inclusion of all three glucose tolerance
groups made it possible to address possible effect
Table 4 Multiple linear regression analysis with autonomic
function tests as dependent variable and homocysteine levels as
independent variable after adjustment for age, gender, glucose
tolerance status, waist-to-hip ratio, serum creatinine, use of
antihypertensives and fasting insulin
Autonomic
function test n B 95% CI for B
LnBRS 534 )0.004 )0.013 to 0.004
LnEI difference 568 )0.006 )0.014 to 0.003
LnHF power 564 )0.009 )0.026 to 0.01
LnLF power 564 )0.003 )0.019 to 0.013
Mean NN 564 )0.94 )3.10 to 1.21
LF/(LF + HF) 564 0.001 )0.001 to 0.004
LnRR max 570 )0.005 )0.01 to 0.001
LnRR max/min 570 0.0004 )0.001 to 0.002
SBP difference 570 )0.14 )0.37 to 0.08
LnSDNN 564 )0.002 )0.009 to 0.004
CADS 530 0.03 )0.05 to 0.11
CADS, combination score of the 10 autonomic function measures;
n, number of subjects on which the analysis was performed. For

































0–25% 25–50% 50–75% 75–100%
Fig. 1 Cardiovascular autonomic dysfunction scores in each
homocysteine quartile for all three glucose tolerance groups.
NGM, normal glucose metabolism; IGM, impaired glucose meta-
bolism; DM, diabetes mellitus.
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modification of glucose tolerance with regard to a
possible association between hyperhomocysteinae-
mia and autonomic dysfunction. The 10 different
measures of autonomic function reflect both para-
sympathetic and sympathetic function, and we were
therefore able to analyse specifically cardiovascular
autonomic function rather than of a mixture of
sensorimotor neuropathy and peripheral and cardial
autonomic neuropathy.
Limitations of our study were the moderate
reproducibility of the test parameters (reliability
coefficient around 50% [31]), reducing the power
of the study and increasing the risk of a type II error.
To enhance power, we constructed a total score
combining the results of all 10 tests, as a single
autonomic function measurement will by definition
show a lower reproducibility than the combination
of several tests. However, such a score has limita-
tions in that there is a lack of knowledge of how
autonomic function measures are interrelated and
whether different weights should be given to separ-
ate tests. An important issue in this respect is
distinction between sympatic and parasympatic
function. Although several of the employed tests
are thought to reflect predominantly either type of
autonomic function [32], most authors agree that a
clear distinction cannot be made [33]. The results of
the combination score were in accordance with the
individual tests. Furthermore, we did not analyse the
results of the autonomic function tests as dichotom-
ous variables for ‘normal’ and ‘abnormal’ results, as
has been done in several previous studies. We chose
this approach because abnormal values for auto-
nomic function tests have been defined on the basis
of statistical abnormality in a healthy control
population, rather than on the basis of pathophys-
iological alterations. There is no evidence to indicate
that these statistically abnormal results have path-
ophysiological significance in the context of a
possible association with hyperhomocysteinaemia.
Finally, B-vitamin levels were not analysed in this
study. The absence of a correlation between hom-
ocysteine and autonomic function does not fully
exclude negative confounding by B-vitamins (i.e. an
association becoming apparent only after adjust-
ment for B-vitamin levels), but we feel this would be
unlikely, because this would imply that high B-
vitamin levels are related to autonomic neuropathy.
However, theoretically this is implausible and there
are no studies showing such an association.
In conclusion, there is no evidence for an associ-
ation between homocysteine levels and cardiovas-
cular autonomic function in either diabetic or non-
diabetic subjects. Cardiovascular autonomic dys-
function thus does not help explain why hyperhom-
ocysteinaemia is related to cardiovascular mortality.
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